Background
Drug-induced severe cutaneous adverse reactions (SCARs) are presumed
T-cell-mediated hypersensitivities associated with significant morbidity
and mortality. Traditional in-vivo testing methods, such as patch
or intradermal testing, are limited by a lack of standardisation and
poor sensitivity. Modern approaches to testing include measurement of
IFN-γ release from patient peripheral blood mononuclear cells (PBMC)
stimulated with the suspected causative drug.